NKECHI PERKINS: Open Payments
NPI 1134617939 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,792 in 15 payments from 9 companies in 2025. Trend: 2023 $865 · 2024 $2,726 · 2025 $1,792
Food & beverage: $1,792
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 3 | $402 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $269 |
| ABBVIE INC. | 2 | $249 |
| AstraZeneca Pharmaceuticals LP | 2 | $240 |
| Teva Pharmaceuticals USA, Inc. | 2 | $174 |
| Alkermes, Inc. | 1 | $123 |
| Biogen, Inc. | 1 | $114 |
| E.R. Squibb & Sons, L.L.C. | 1 | $112 |
| Stryker Corporation | 1 | $109 |
Products named: INVEGA SUSTENNA, CAPLYTA, VRAYLAR, UZEDY, LYBALVI, DATROWAY, BREZTRI, ZURZUVAE.
Industry payments across CA — which companies pay providers there.
